RxDoctor Payments Data

Lisa Jambusaria, MD

Urogynecology and Reconstructive Pelvic Surgery · Nashville, TNNPI 1497982003

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,458 of the $5,100 with a category attached, or 67.8%. 11 manufacturers reported payments, led by Medtronic at 39.2% of the total. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TN, where the typical reported total is $5,304.

$5,100in general payments, 2019–2025

Across 90 payments — averaging $56.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$2K
  • Coloplast$338
  • Astellas Pharma US Inc$268
  • Axonics, Inc.$185
  • Laborie Medical Technologies Corp.$155
  • plus $374 from 5 others

What the payments were for

  • Travel & lodging$1,46229%
  • Food & beverage$3,45868%
  • Education$1523%
  • Gifts$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,100 in reported general payments places this provider in the 45th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.

See all urogynecology and reconstructive pelvic surgery providers in Tennessee

Medicare billing

Part B allowed, 2024
$166,925
Medicare patients
159
Services billed
2,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron159$105,075
MyrbetriqMirabegron35$20,196
Estradiol252$15,784
Trospium Chloride ErTrospium Chloride36$7,336
Clobetasol Propionate12$818
Ibuprofen58$280
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$213
Fluconazole22$167
Oxycodone Hcl64$159
Cephalexin27$143
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$98
Ondansetron Hcl15$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$66$105,075159 claims
Astellas Pharma US IncMyrbetriq$268$20,19635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.

Other urogynecology and reconstructive pelvic surgery in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →